Double Blind Comparative Study of TAK-875

• Status: Completed
• Trial end date: 2012-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the efficacy and safety of treatment with TAK-875 in diabetic patients.

• Phase: Phase 3

Details

• Lead Sponsor: Takeda
• Treatments: Glimepiride

Criteria

Inclusion Criteria:

• The participant is an outpatient.

• The participant signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.

Exclusion Criteria:

• The participant has any serious cardiac disease, serious cerebrovascular disorder, or any serious pancreatic or hematological disease.

• The participant is considered ineligible for the study for any other reason by the investigator or subinvestigator.